Imiquimod enhances excitability of dorsal root ganglion neurons by inhibiting background (K2P) and voltage-gated (Kv1.1 and Kv1.2) potassium channels
© Lee et al.; licensee BioMed Central Ltd. 2012
Received: 26 October 2011
Accepted: 11 January 2012
Published: 11 January 2012
Imiquimod (IQ) is known as an agonist of Toll-like receptor 7 (TLR7) and is widely used to treat various infectious skin diseases. However, it causes severe itching sensation as its side effect. The precise mechanism of how IQ causes itching sensation is unknown. A recent report suggested a molecular target of IQ as TLR7 expressed in dorsal root ganglion (DRG) neurons. However, we recently proposed a TLR7-independent mechanism, in which the activation of TLR7 is not required for the action of IQ in DRG neurons. To resolve this controversy regarding the involvement of TLR7 and to address the exact molecular identity of itching sensation by IQ, we investigated the possible molecular target of IQ in DRG neurons.
When IQ was applied to DRG neurons, we observed an increase in action potential (AP) duration and membrane resistance both in wild type and TLR7-deficient mice. Based on these results, we tested whether the treatment of IQ has an effect on the activity of K+ channels, Kv1.1 and Kv1.2 (voltage-gated K+ channels) and TREK1 and TRAAK (K2P channels). IQ effectively reduced the currents mediated by both K+ channels in a dose-dependent manner, acting as an antagonist at TREK1 and TRAAK and as a partial antagonist at Kv1.1 and Kv1.2.
Our results demonstrate that IQ blocks the voltage-gated K+ channels to increase AP duration and K2P channels to increase membrane resistance, which are critical for the membrane excitability of DRG neurons. Therefore, we propose that IQ enhances the excitability of DRG neurons by blocking multiple potassium channels and causing pruritus.
Imiquimod (IQ) is widely used to treat various skin diseases such as molluscum contagiosum, basal cell carcinoma, and Bowen's disease . Topical application of the compound is currently approved for treatment of genital warts, a highly contagious sexually transmitted disease caused by human papillomavirus [1–5]. It is believed that IQ modulates immune responses via Toll-like receptor 7 (TLR7) releasing IFN-α/β and proinflammatory cytokines . Nevertheless, the exact mechanism of how IQ activates the immune system is not fully understood. Despite its clinical importance, the most prominent side effect of IQ is pruritus, e.g. itching sensation [7, 8]. The mechanism of how IQ causes itching sensation has remained unknown.
Recently we and others reported that IQ-induced depolarization in dorsal root ganglion (DRG) neurons leads to itching behavior [7, 8]. Even though these two studies agreed upon IQ's action on the cellular and behavioral level, there was a profound discrepancy on the molecular target of IQ. The study by Liu et al. reported that membrane depolarization caused by IQ required TLR7 to generate action potentials (APs) and to induce itching behavior . On the contrary, our study independently demonstrated that the action of IQ does not require the TLR7 pathway . In this study, we showed that IQ caused depolarization and AP firing in DRG neurons of both wild type (WT) and TLR7 knock out (KO) mice. Our results suggested that IQ induced depolarization and AP firing, not by TLR7 signal transduction, but by the direct effect on other channels .
DRG neurons express many types of potassium channels including voltage-gated (Kv), inwardly rectifying (Kir), Ca2+-activated (KCa) and background (leak, K2P) K+ channels. These channels contribute to the regulation of membrane repolarization, resting membrane potential, frequency of firing, and excitability of sensory neurons [9, 10]. Among various K+ channels, Kv channels play a crucial role in returning the depolarized cell to the resting state, and the inhibition of these channels leads to AP broadening (for review see ). In addition, DRG neurons express at least eight K2P channel subtypes as reported at the mRNA transcript level [12, 13]. K2P channels help to set, and stabilize the resting membrane potential and closing of these channels leads to membrane depolarization . In our preliminary analysis of the results, we found an increase in membrane resistance and duration of AP during IQ treatment. Therefore, we systematically tested the possible molecular target of IQ on K+ channels. Our results demonstrate that IQ effectively inhibits Kv and K2P channels in DRG neurons.
Then, we examined the change of input resistance by IQ in WT. The measurement of input resistance by the injection of negative current indicated that background leak channel activity was altered by IQ treatment (Figure 1B). Membrane resistance of WT and TLR7 KO was similar (593 ± 52.39 MΩ (n = 6) in WT control; 531 ± 151.99 MΩ (n = 6) in TLR7 KO) and IQ significantly increased membrane resistance in WT (165.66 ± 13.82% (n = 7), P < 0.01) and KO (128.11 ± % (n = 9), P < 0.05). These results indicated that IQ depolarizes the membrane potential and increase AP duration in DRG neurons, and that these effects might not be due to the activation of TLR7 signaling pathway. Rather, these results strongly suggested IQ's direct targeting on ion channel(s), in particular, potassium channels.
Clinically, IQ has been known as a topically active immunomodulatory agent that is formulated as a 5% cream for application by the patient of skin diseases. IQ 5% cream is generally well tolerated by immunocompetent and HIV-infected patients. Local skin reactions (mainly mild or moderate), including erythema, itching and burning, are the most commonly reported adverse events, occurring in < or = 67% of patients applying IQ 5% cream 3 times a week [1, 5]. So far, the mechanism of how IQ causes the adverse side-effects has been unknown. In this study, we demonstrate, for the first time, that IQ inhibits Kv1.1and Kv1.2 and TREK1 and TRAAK. These results can explain the IQ's action of increasing the excitability of sensory neurons. This, in turn, could explain the ability of IQ to induce itching sensation.
In our previous study, we described various actions of IQ such as membrane depolarization, action potential firing, increase in intracellular Ca2+ concentration, and itching behavior . We found that IQ can directly excite DRG neurons most likely by blocking Kv and K2P channels. For IQ-induced Ca2+ response, we found that it was not altered by external Ca2+, but was completely blocked by the application of 2-aminoethoxydiphenyl borate (2-APB), an inhibitor of inositol trisphosphate receptor (IP3R) . Therefore, IQ seems to act on many molecular targets including Ca2+ release channels as well as various potassium channels in sensory neurons. Our data from the heterologous expression system using COS7 cells that lacks TLR7 re-confirm that IQ effects are TLR7-independent, and suggest that it rather directly acts on potassium channels in sensory neurons. In this study, we have not characterized the putative cross-talk between IQ-induced Ca2+ increase and potassium channel block. Thus, at this point, it is not clear whether IQ inhibits potassium channels independently of intracellular Ca2+ increase, which needs to be clarified in the future studies.
Although there are many channels contributing to membrane depolarization and generation of action potential in neurons, various K+ channels exert an important role in repolarizing membrane potentials and maintaining AP duration. Among many types of potassium channels expressed in DRG neurons, Kv1.1, Kv1.2, Kvβ2.1 and Kv1.4 were reported as voltage-gated channels that regulate membrane repolarization, resting membrane potential, frequency of firing, and neurotransmitter release in sensory neurons . Background K+ channels have been implicated in various important physiological functions including mechano-, lipid-, acid- and possibly oxygen-sensing in specialized cells. In neurons, it was reported that these channels help to set and stabilize the resting membrane potential . Our results demonstrate that IQ blocks K+ channels (Kv and K2P), thereby enhancing the excitability of DRG neurons. Our results provide a possible explanation for how IQ causes pruritius. Yet, the detailed mechanism of how IQ can lead to itching sensation by blocking various potassium channels remains to be uncovered.
Materials and methods
All experimental procedures described below were performed in accordance with the institutional guidelines of KIST (Seoul, Korea). TLR7-deficient mice were purchased from Jackson Laboratory. They were crossed with wild-type C57BL/6 (2-month-old, Charles River) to produce heterozygous mice. The resultant heterozygous mice were used as mating pairs. More detail methods maintaining TLR7 strain were previously described . Specifically, the Jackson Laboratory TLR7 mouse was originally established by R. Flavell's laboratory (Yale University, New Haven, CT). Littermates or age-matched mice were generally used as wild type controls.
Preparation of Primary DRG Cell Culture
DRG neurons were prepared from adult mice (~2 month old) by methods similar to those described previously [15, 16]. Briefly, DRG from all spinal levels were collected in Ca2+/Mg2+-free Hanks' balanced salt solution (HBSS; Invitrogen) and treated with enzyme solution containing 60 units of papain/cystein (0.33 mg/mL), 5 mg/mL of Dispase, and 4 mg/mL of collagenase (Gibco) for 10 min at 37°C, respectively. Following trituration and centrifugation, the dispersed cells were resuspended in DMEM/F12 culture media containing 10% FBS [nerve-growth factor (NGF) or glial cell line-derived neurotropic factor (GDNF) was not included in culture medium] and were plated in 35-mm poly D-lysine precoated glass-bottomed dishes (MatTek) coated with laminin. Cultures were maintained at 37°C in a humidified atmosphere of 95% air and 5% CO2 and assayed after 16-20 h.
DRG neuron whole cell recording
Acutely dissociated DRG neurons were obtained from C57BL/6 and TLR7 KO mice (8-10 wks) and attached to coverslips for recording. Before recording, coverslips were incubated in media for at least 1 h. DRG neuron recordings were performed in HEPES buffer of the following composition (in mM): 10 HEPES, 150 NaCl, 10 KCl, 2 CaCl2, 2 MgCl2, 5.5 glucose, and 22 sucrose (pH 7.4). Under the upright microscope, whole-cell patch recordings were obtained from acute-isolate DRG neurons in voltage-clamp mode and switched current-clamp configuration for recordings with an Axopatch 700B (Molecular Devices). Pipette resistance ranged from 3 to 6 MΩ. The internal solution consisted of (in mM) 140 K-gluconate, 10 Hepes, 7 NaCl, 4 Mg-ATP, and 0.3 Na3-GTP (pH 7.4). Firing properties were established for 1,000-ms duration by applying current injection from -100 to 350 pA with 50 pA increase. The cells with access resistance less than 20 MΩ that showed less than 20% change during the recordings were included in this study. Records were filtered at 5 kHz and digitized at 2-5 kHz with a Digidata 1322A (Molecular Devices) analog-to-digital board. Data were analyzed and plotted with the pClamp (Molecular Devices), Mini Analysis Program (Synaptosoft), and Origin. All data were collected at room temperature (23-26°C).
COS7 Cell Culture and Transfection of plasmid DNA
COS 7 cells are cultured in high-glucose DMEM (Invitrogen) containing 10% FBS, and 100 U/ml penicillin/streptomycin, and maintained at 37°C in a 5% CO2 incubator. Transfections of plasmid DNA containing rat Kv1.1 (Genbank: NM_017303) and rat Kv1.2 (Genbank: NM_012970) and mouse TREK1 (Genbank: NM_010607) and rat TRAAK (Genbank: NM_053804) were performed with Effectene transfection reagent (Qiagen). Protocols were conformed to the product guideline description. Condition of recording and internal solution was same with the condition of recording DRG neurons.
This work was supported by the World Class Institute (WCI) Program of the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology of Korea (MEST) (NRF Grant Number: WCI 2009-003) for Dr. CJL and was supported by NRF funded by MEST (No. 2011-0018277, 2011-0000934, and 2011-0027667) for Dr. SJL.
- Syed TA: A review of the applications of imiquimod: a novel immune response modifier. Expert opinion on pharmacotherapy 2001,2(5):877–882.View ArticlePubMedGoogle Scholar
- Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML: Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. Journal of the American Academy of Dermatology 1999,41(6):1002–1007. 10.1016/S0190-9622(99)70261-6View ArticlePubMedGoogle Scholar
- Buckley R, Smith K: Topical imiquimod therapy for chronic giant molluscum contagiosum in a patient with advanced human immunodeficiency virus 1 disease. Archives of dermatology 1999,135(10):1167–1169. 10.1001/archderm.135.10.1167View ArticlePubMedGoogle Scholar
- van Egmond S, Hoedemaker C, Sinclair R: Successful treatment of perianal Bowen's disease with imiquimod. International journal of dermatology 2007,46(3):318–319. 10.1111/j.1365-4632.2007.03200.xView ArticlePubMedGoogle Scholar
- Perry CM, Lamb HM: Topical imiquimod: a review of its use in genital warts. Drugs 1999,58(2):375–390. 10.2165/00003495-199958020-00017View ArticlePubMedGoogle Scholar
- Stanley MA: Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clinical and experimental dermatology 2002,27(7):571–577. 10.1046/j.1365-2230.2002.01151.xView ArticlePubMedGoogle Scholar
- Kim SJ, Park GH, Kim D, Lee J, Min H, Wall E, Lee CJ, Simon MI, Lee SJ, Han SK: Analysis of cellular and behavioral responses to imiquimod reveals a unique itch pathway in transient receptor potential vanilloid 1 (TRPV1)-expressing neurons. Proceedings of the National Academy of Sciences of the United States of America 2011,108(8):3371–3376. 10.1073/pnas.1019755108PubMed CentralView ArticlePubMedGoogle Scholar
- Liu T, Xu ZZ, Park CK, Berta T, Ji RR: Toll-like receptor 7 mediates pruritus. Nature neuroscience 2010,13(12):1460–1462. 10.1038/nn.2683PubMed CentralView ArticlePubMedGoogle Scholar
- Rasband MN, Park EW, Vanderah TW, Lai J, Porreca F, Trimmer JS: Distinct potassium channels on pain-sensing neurons. Proceedings of the National Academy of Sciences of the United States of America 2001,98(23):13373–13378. 10.1073/pnas.231376298PubMed CentralView ArticlePubMedGoogle Scholar
- Takeda M, Tsuboi Y, Kitagawa J, Nakagawa K, Iwata K, Matsumoto S: Potassium channels as a potential therapeutic target for trigeminal neuropathic and inflammatory pain. Molecular pain 2011, 7: 5. 10.1186/1744-8069-7-5PubMed CentralView ArticlePubMedGoogle Scholar
- Roeper J, Pongs O: Presynaptic potassium channels. Current opinion in neurobiology 1996,6(3):338–341. 10.1016/S0959-4388(96)80117-6View ArticlePubMedGoogle Scholar
- Medhurst AD, Rennie G, Chapman CG, Meadows H, Duckworth MD, Kelsell RE, Pangalos MN: Distribution analysis of human two pore domain potassium channels in tissues of the central nervous system and periphery. Brain research Molecular brain research 2001,86(1–2):101–114.View ArticlePubMedGoogle Scholar
- Maingret F, Lauritzen I, Patel AJ, Heurteaux C, Reyes R, Lesage F, Lazdunski M, Honore E: TREK-1 is a heat-activated background K(+) channel. The EMBO journal 2000,19(11):2483–2491. 10.1093/emboj/19.11.2483PubMed CentralView ArticlePubMedGoogle Scholar
- Kang D, Kim D: TREK-2 (K2P10.1) and TRESK (K2P18.1) are major background K+ channels in dorsal root ganglion neurons. American journal of physiology Cell physiology 2006,291(1):C138–146. 10.1152/ajpcell.00629.2005View ArticlePubMedGoogle Scholar
- Johanek LM, Meyer RA, Friedman RM, Greenquist KW, Shim B, Borzan J, Hartke T, LaMotte RH, Ringkamp M: A role for polymodal C-fiber afferents in nonhistaminergic itch. The Journal of neuroscience: the official journal of the Society for Neuroscience 2008,28(30):7659–7669. 10.1523/JNEUROSCI.1760-08.2008View ArticleGoogle Scholar
- Andrew D, Craig AD: Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch. Nature neuroscience 2001,4(1):72–77. 10.1038/82924View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.